scholarly journals Cost effectiveness of a general practice chronic disease management plan for coronary heart disease in Australia

2010 ◽  
Vol 34 (2) ◽  
pp. 162 ◽  
Author(s):  
Derek P. Chew ◽  
Robert Carter ◽  
Bree Rankin ◽  
Andrew Boyden ◽  
Helen Egan
Keyword(s):  
Coronary Heart Disease ◽  
General Practice ◽  
Heart Disease ◽  
Chronic Disease ◽  
Cost Effectiveness ◽  
Disease Management ◽  
Financial Incentives ◽  
Chronic Disease Management ◽  
Cost Effective ◽  
Disease Registry

Background.The cost effectiveness of a general practice-based program for managing coronary heart disease (CHD) patients in Australia remains uncertain. We have explored this through an economic model. Methods.A secondary prevention program based on initial clinical assessment and 3 monthly review, optimising of pharmacotherapies and lifestyle modification, supported by a disease registry and financial incentives for quality of care and outcomes achieved was assessed in terms of incremental cost effectiveness ratio (ICER), in Australian dollars per disability adjusted life year (DALY) prevented. Results.Based on 2006 estimates, 263 487 DALYs were attributable to CHD in Australia. The proposed program would add $115 650 000 to the annual national heath expenditure. Using an estimated 15% reduction in death and disability and a 40% estimated program uptake, the program’s ICER is $8081 per DALY prevented. With more conservative estimates of effectiveness and uptake, estimates of up to $38 316 per DALY are observed in sensitivity analysis. Conclusions.Although innovation in CHD management promises improved future patient outcomes, many therapies and strategies proven to reduce morbidity and mortality are available today. A general practice-based program for the optimal application of current therapies is likely to be cost-effective and provide substantial and sustainable benefits to the Australian community. What is known about this topic?Chronic disease management programs are known to provide gains with respect to reductions in death and disability among patients with coronary heart disease. The cost effectiveness of such programs in the Australian context is not known. What does this paper add?This paper suggests that implementing a coronary heart disease program in Australia is highly cost-effective across a broad range of assumptions of uptake and effectiveness. What are the implications for practitioners? These data provide the economic rationale for the implementation of a chronic disease management program with a disease registry and regular review in Australia.

Outcomes and opportunities: a nurse-led model of chronic disease management in Australian general practice

2013 ◽  
Vol 19 (2) ◽  
pp. 150 ◽  
Author(s):  
Diann S. Eley ◽  
Elizabeth Patterson ◽  
Jacqui Young ◽  
Paul P. Fahey ◽  
Chris B. Del Mar ◽  
...  
Keyword(s):  
Quality Of Life ◽  
General Practice ◽  
Chronic Disease ◽  
Disease Management ◽  
Chronic Disease Management ◽  
Models Of Care ◽  
Practice Nurses ◽  
Australian General Practice ◽  
General Practices

The Australian government’s commitment to health service reform has placed general practice at the centre of its agenda to manage chronic disease. Concerns about the capacity of GPs to meet the growing chronic disease burden has stimulated the implementation and testing of new models of care that better utilise practice nurses (PN). This paper reports on a mixed-methods study nested within a larger study that trialled the feasibility and acceptability of a new model of nurse-led chronic disease management in three general practices. Patients over 18 years of age with type 2 diabetes, hypertension or stable ischaemic heart disease were randomised into PN-led or usual GP-led care. Primary outcomes were self-reported quality of life and perceptions of the model’s feasibility and acceptability from the perspective of patients and GPs. Over the 12-month study quality of life decreased but the trend between groups was not statistically different. Qualitative data indicate that the PN-led model was acceptable and feasible to GPs and patients. It is possible to extend the scope of PN care to lead the routine clinical management of patients’ stable chronic diseases. All GPs identified significant advantages to the model and elected to continue with the PN-led care after our study concluded.

Cost-effectiveness of a chronic disease management model for cirrhosis: Analysis of a randomized controlled trial

2018 ◽  
Vol 33 (9) ◽  
pp. 1634-1640 ◽  
Author(s):  
Alan J Wigg ◽  
Jong K Chin ◽  
Kate R Muller ◽  
Jeyamani Ramachandran ◽  
Richard J Woodman ◽  
...  
Keyword(s):  
Randomized Controlled Trial ◽  
Chronic Disease ◽  
Cost Effectiveness ◽  
Disease Management ◽  
Chronic Disease Management ◽  
Controlled Trial ◽  
Management Model ◽  
Randomized Controlled

Building quality chronic illness care: implementation of a web-based care plan

2020 ◽  
Vol 26 (2) ◽  
pp. 173
Author(s):  
Shiva Vasi ◽  
Jenny Advocat ◽  
Akuh Adaji ◽  
Grant Russell
Keyword(s):  
Primary Care ◽  
General Practice ◽  
Chronic Disease ◽  
Disease Management ◽  
Chronic Disease Management ◽  
New Technologies ◽  
Participant Observation ◽  
Care Plan ◽  
Structured Interviews ◽  
Structured Approach

Structured, multidisciplinary approaches to chronic disease management (CDM) in primary care, supported by eHealth tools, show improved clinical outcomes, yet the uptake of eHealth tools remains low. The adoption of cdmNet, an eHealth tool for chronic disease management, in general practice settings, was explored. This was a qualitative case study in three general practice clinics in Melbourne, Australia. Methods included non-participant observation, reflexive note taking and semi-structured interviews with GPs, non-GP clinical staff, administrative staff and patients with chronic conditions. Data were analysed iteratively and results were reviewed at regular team meetings. Findings highlighted the significance of clinical and organisational routines in determining practice readiness for embedding innovations. In particular, clinical routines that supported a structured approach to CDM involving team-based care, allocation of resources, training and leadership were fundamental to facilitating the adoption of the eHealth tool. Non-GP roles were found to be key in developing routines that facilitated the adoption of cdmNet within a structured approach to CDM. Practice managers, administrators and clinicians should first focus on routinising processes in primary care practices that support structured and team-based processes for CDM because without these processes, new technologies will not be embedded.

Primary prevention of cardiovascular disease: Cost-effectiveness comparison

2007 ◽  
Vol 23 (1) ◽  
pp. 71-79 ◽  
Author(s):  
Oscar H. Franco ◽  
Arno J. der Kinderen ◽  
Chris De Laet ◽  
Anna Peeters ◽  
Luc Bonneux
Keyword(s):  
Cardiovascular Disease ◽  
Coronary Heart Disease ◽  
Smoking Cessation ◽  
Heart Disease ◽  
Cost Effectiveness ◽  
Primary Prevention ◽  
Risk Reduction ◽  
Cost Effective ◽  
Life Years ◽  
Prevention Of Cardiovascular Disease

Objectives: The aim of this study was to evaluate the cost-effectiveness of four risk-lowering interventions (smoking cessation, antihypertensives, aspirin, and statins) in primary prevention of cardiovascular disease.Methods: Using data from the Framingham Heart Study and the Framingham Offspring study, we built life tables to model the benefits of the selected interventions. Participants were classified by age and level of risk of coronary heart disease. The effects of risk reduction are obtained as numbers of death averted and life-years saved within a 10-year period. Estimates of risk reduction by the interventions were obtained from meta-analyses and costs from Dutch sources.Results: The most cost-effective is smoking cessation therapy, representing savings in all situations. Aspirin is the second most cost-effective (€2,263 to €16,949 per year of life saved) followed by antihypertensives. Statins are the least cost-effective (€73,971 to €190,276 per year of life saved).Conclusions: A cost-effective strategy should offer smoking cessation for smokers and aspirin for moderate and high levels of risk among men 45 years of age and older. Statin therapy is the most expensive option in primary prevention at levels of 10-year coronary heart disease risk below 30 percent and should not constitute the first choice of treatment in these populations.

Sign in / Sign up

Export Citation Format

Share Document